product name Batimastat (BB-94)
Description: Batimastat (also known as BB-94) is a potent, synthetic, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. It also inhibits the activitity of other metalloproteases, such as ADAM17. It exhibits antineoplastic and antiangiogenic activity in various tumor models, including ovarian carcinoma xegnografts and human colon tumor.
References: Int J Cancer. 1994 Aug 1;58(3):460-4; Cancer Res. 1994 Sep 1;54(17):4726-8.
477.64
Formula
C23H31N3O4S2
CAS No.
130370-60-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 96 mg/mL (201.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
30% propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL
Synonyms
BB-94
other peoduct :
| In Vitro |
In vitro activity: Batimastat (BB-94) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. Batimastat exhibits an unexpected binding geometry, with the thiophene ring deeply inserted into the primary specificity site. Kinase Assay: Cell Assay: In vitro proliferation in the presence of batimastatwas assessed by the MTT absorbance assay. The effect of batimastat on the in vitro growth of C170HM2 and AP5LV in both serum-free and scrum-containing culture media was determined three times. Batimastat had no significant effect on the growth of either cell line. |
|---|---|
| In Vivo | Batimastat can inhibit metastatic spread and growth of B16-BL6 murine melanoma. In an orthotopic colon tumor model in mice, timastat treatment results in inhibition of primary tumor growth (by 50%), local/regional spread(from 67% to 35%), and distant metastasis(from 30% to 10%). Batimastat reduces in vivo growth of experimental hemangiomas, most probably by blocking endothelial cell recruitment by the transformed cells or by interfering with cell organization in vascular structures. |
| Animal model | Nude mice |
| Formulation & Dosage | Dissolved in PBS containing 0.01% Tween 2O; 30 mg/kg; i.p. injection |
| References | Int J Cancer. 1994 Aug 1;58(3):460-4; Cancer Res. 1994 Sep 1;54(17):4726-8; J Natl Cancer Inst. 1995 Feb 15;87(4):293-8. |
